Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2014 Dec;52(12):4388–4390. doi: 10.1128/JCM.02782-14

A Novel Pseudomonas aeruginosa Strain with an oprD Mutation in Relation to a Nosocomial Respiratory Infection Outbreak in an Intensive Care Unit

Yingjun Yan a,b, Xiangyu Yao c, Haijing Li b, Zhonghua Zhou a, Wenfang Huang a, Charles W Stratton b, Chung-Dar Lu c, Yi-Wei Tang b,d,e,
Editor: E Munson
PMCID: PMC4313324  PMID: 25297323

Abstract

Seven imipenem-resistant Pseudomonas aeruginosa isolates were recovered from the sputum samples of pneumonia patients in southwestern China. They had identical antibiotic resistance patterns and indistinguishable pulsed-field gel electrophoresis profiles. Nucleotide sequence analysis revealed a 4-bp (AGTC) insertion in the oprD gene, resulting in a frameshift in the cognate open reading frame. These isolates became imipenem susceptible when the chromosomal oprD lesion was complemented, indicating that the 4-bp insertion in the oprD gene resulted in imipenem resistance.

INTRODUCTION

Carbapenems are considered to be excellent antimicrobial agents and are frequently used for the treatment of hard-to-manage Pseudomonas aeruginosa infections. However, carbapenem resistance in P. aeruginosa has been reported to increase steadily over the years across the United States (1). In China, 10.6% of P. aeruginosa species are resistant to imipenem, most of which have been multidrug-resistant isolates based on Mohnarin 2004 to 2005 (2). From April to September 2009, the Emergency Intensive Care Unit (EICU) in a provincial hospital in southwestern China had an outbreak of imipenem-resistant P. aeruginosa (IRPA) in seven patients. In this study, we reviewed patient medical records, as well as the phenotypes and genotypes of the seven isolates recovered from the patients, and we investigated the main mechanism of resistance to imipenem.

(This study was presented in part at the 111th Annual Meeting of the American Society for Microbiology, New Orleans, LA, 21 to 24 May 2011.)

Hospital setting and patients.

The following data were recorded from the medical charts of patients with P. aeruginosa infection: age, gender, number of patient-days in the hospital, diagnosis, susceptibility pattern, and clinical outcome. Only one sample with P. aeruginosa per patient was enrolled in this study. This study was approved by the research ethics committee of the Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital.

Bacterial strains and antimicrobial susceptibility testing.

Nonduplicated IRPA clinical isolates recovered in 2009 were included in this study. Those isolates were identified and antimicrobial susceptibility testing performed using the BD Phoenix 100 automatic microbial analysis system (Becton Dickinson Microbiology Systems, Sparks, MD, USA). The MIC of imipenem was determined by using the Etest technique (AB Biodisk, Solna, Sweden). The results were expressed as susceptible (S) or resistant (R), according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (3). P. aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were used as reference strains in the antimicrobial susceptibility testing. P. aeruginosa strain PAO1 was used as an OprD-positive reference strain to detect and analyze the oprD gene and OprD outer membrane porin protein.

Molecular typing by pulsed-field gel electrophoresis.

A total of 19 out of 392 IPRA strains with the same antimicrobial phenotypes were suspected to be clonally transmitted. Pulsed-field gel electrophoresis (PFGE) was employed to differentiate the genotypes, as previously described (4).

PCR amplification and sequencing of oprD.

P. aeruginosa genome DNA extraction and PCR amplification of the oprD gene was performed as previously described (5). Distilled water and PAO1 genomic DNA derived from a reference strain of P. aeruginosa were used as negative and positive controls, respectively. Sequencing of the amplicons was done on both strands with an ABI Prism 377A sequencer analyzer (Applied Biosystems). The nucleotide sequences were determined bidirectionally and compared with those of the reference strain P. aeruginosa PAO1.

oprD complementation tests and outer membrane protein analysis.

The pAU48 plasmid, which carries the wild-type oprD gene and its promoter region of P. aeruginosa PAO1 in vector pAU47, was employed for the complementation tests. The construction of pAU48 was described in detail in a previous report (6). The standard protocol for competent cell preparation and transformation (7) was used for the introduction of pAU47 and pAU48 into strains of P. aeruginosa, as indicated in that study. The transformants were selected on the LB plates containing tetracycline (100 μg/ml), and the presence of plasmids in the resulting recombinant strains was confirmed by plasmid preparation and restriction digestion. Outer membrane proteins were isolated according to the procedures of Carlone et al. (8)

In 2009, 1,178 P. aeruginosa isolates were recovered in the hospital, and 392 (33.3%) were imipenem resistant. The molecular typing of the 19 isolates revealed 9 subgroups (A to I) in PFGE, with the most frequent (subgroup F) being represented by seven isolates (P. aeruginosa clinical isolates 85, 373, 483, 599, 2703, 2860, and 2876). All were recovered from sputum specimens from patients with hospital-acquired pneumonia in the EICU from April to September 2009, which indicated clonal transmission in the EICU.

The clinical characteristics of seven patients from whom P. aeruginosa was isolated are shown in Table 1. PCR was first conducted to verify the existence of oprD in the clinical isolates recovered from the seven EICU patients. Sequence analysis of the oprD genes revealed that nucleotide sequences of the 5′ and 3′ ends of oprD were highly conserved among all strains of P. aeruginosa available in the NCBI database. Accordingly, two oligonucleotide primers with conserved sequences covering these two regions of oprD were designed and applied for PCR. All strains tested positive (data not shown), indicating the presence of oprD in the genome.

TABLE 1.

Clinical characteristics of seven EICU patients infected with IRPAa

Case Isolate Gender/age (yr) Length of hospitalization (days) Day of isolation Diagnosis Antibiotic(s) administered Outcome
1 85 Male/78 >365 40 Obstructive pulmonary emphysema Ceftazidime, levofloxacin, ertapenem Improvement
2 373 Male/73 7 17 Pneumonia, II respiratory failure, pulmonary encephalopathy Amikacin, ciprofloxacin, imipenem, piperacillin-tazobactam, azithromycin, roxithromycin Improvement
3 483 Male/40 107 39 Primary brain stem injury Teicoplanin, amikacin, meropenem, voriconazole Improvement
4 599 Male/83 24 11 Obstructive pulmonary emphysema II respiratory failure cefoperazone-sulbactam, teicoplanin, amikacin Death
5 2703 Male/82 17 7 Lung aspiration pneumonia Meropenem, teicoplanin Cured
6 2860 Male/80 38 30 Obstructive pulmonary emphysema Meropenem Improvement
7 2876 Male/70 24 15 Extensive abdominal abscess Meropenem, amikacin Cured
a

These 7 patients all experienced ventilator, deep-vein catheterization, and a urine catheter in the EICU. All patients had mixed infections after P. aeruginosa was isolated the first time. The most common pathogens isolated from mixed infection were methicillin-resistant Staphylococcus aureus, A. baumannii, E. coli, Klebsiella pneumoniae, and Candida albicans.

To further characterize the genetic lineage of oprD in the seven isolates, the nucleotide sequences of oprD from the isolates were determined. Sequence alignment indicated that all these oprD genes possess a completely identical sequence. A BLAST search against the NCBI database showed that the coding sequence of this oprD gene is identical to that in P. aeruginosa strain MTB-1 (GenBank accession no. CP006853) (9) except for a 4-bp AGTC insertion after nucleotide position 752 in the oprD gene found this study. The amino acid sequence of MTB-1 OprD of 441 residues exhibited 93% sequence identity to that of the reference strain PAO1 of 443 residues. In comparison, the 4-bp insertion in the mutated oprD gene (whose product is designated OprD-M) resulted in a reading frameshift and premature termination in the translated peptide of 264 residues in length, which was truncated after the putative loop 4 of the OprD protein. These data suggest that the truncated OprD-M forms a nonfunctional outer membrane porin in the seven EICU isolates of this study.

To test the hypothesis that a truncated nonfunctional OprD-M in these isolates was responsible for imipenem resistance, we conducted the following complementation tests in PAO1 and isolates 373 and 599, two of the seven EICU strains. For each strain, plasmids pAU47 and pAU48 (pAU47 carrying the oprD gene of PAO1) were introduced into the host, and the MICs of imipenem in these transformants were determined by the broth dilution method to be 1 μg/ml for PAO1/pAU47, 0.5 μg/ml for PAO1/pAU48, >8 μg/ml for 373/pAU47, 0.5 μg/ml for 373/pAU48, >8 μg/ml for 599/pAU47, and 0.5 μg/ml for 599/pAU48. The apparent >4-fold reduction in the MICs of strains 373 and 599 harboring pAU48 supported a defect in oprD as the cause of imipenem resistance in these strains.

The outer membrane porin profiles of these strains were also determined. The outer membrane proteins were separated by SDS-PAGE and stained with Coomassie brilliant blue R-250. Both strains 373 and 599 lacked the corresponding band for OprD in comparison to that of PAO1, and the introduction of pAU48 into these strains exhibited an increased level of OprD (Fig. 1). These results indicated the absence of functional OprD in the clinical isolates of this study.

FIG 1.

FIG 1

Outer membrane profiling determined by SDS-PAGE. PAO1, reference strain of P. aeruginosa; 373 and 599, representative clinical isolates. PAO1/pAU48, 373/pAU48, 599/pAU48, strains harboring the plasmid-borne oprD. M, molecular size marker. The banding position of OprD is indicated by the arrow on the upper right.

Imipenem resistance is usually multifactorial. The increased production of carbapenem-hydrolyzing enzymes (mainly metallo-β-lactamases [MBLs]), the production of AmpC chromosome-encoded cephalosporinase, and reduced outer membrane porin OprD expression are known to contribute to imipenem resistance (10). Our previous study showed that the main resistance mechanisms for imipenem in our hospital did not produce carbapenem-hydrolyzing enzymes, AmpC chromosome-encoded cephalosporinase, or active efflux system overexpression (11). The mutational inactivation of the oprD gene represents the major cause of OprD loss in ICU P. aeruginosa strains (12). In China, it was reported that carbapenem resistance was driven mainly by mutational inactivation of OprD (13).

The oprD gene was reported as an interesting genetic marker not only because of its contribution to carbapenem resistance but also its high sequence variability for clonal analysis (14). It was found that although the virtually unlimited number of oprD alleles provides high discriminatory power, members of narrow clonal lineages often show identical oprD sequences. In this study, several lines of evidence support the conclusion that the carbapenem-resistant phenotype of these clinical isolates was due to the lack of a functional OprD porin. Since the oprD coding sequences of these isolates were all identical, it is very likely that they originated from the same clone, which may be very closely related to strain MTB-1, an environmental isolate (9). The results of a BLAST tree analysis revealed additional clan members other than MTB-1. These members include a Spanish carbapenem-resistant isolate, P. aeruginosa W64 (GenBank accession no. KF517098), which has a transposon insertion at the 5′ end of oprD, and several clinical carbapenem-resistant isolates from Lebanon (GenBank accession no. KJ482581, KJ482584, KJ482596, and KJ482597), which have different base substitutions resulting in the introduction of premature termination codons. However, none of these strains had the 4-bp insertion in oprD as discovered in this study. This new type of oprD mutation as discovered in this study might be the result of selection pressure in clinical settings.

P. aeruginosa OprD is a 443-amino-acid protein that facilitates the uptake of basic amino acids, imipenem, and gluconate across the outer membrane. Huang and colleagues (15) proposed an OprD topology model in which 16 beta-strands were predicted, connected by short loops at the periplasmic side. The eight external loops (L1 to L8) were of varied lengths but tended to be much longer than the periplasmic ones. In this study, the 4-bp insertion mutation at nucleotide (nt) 752 resulted in the OprD protein being truncated after loop 4. It was further confirmed that a novel 4-bp insertion in the oprD gene caused the defect in OprD function and resulted in imipenem resistance.

Nucleotide sequence accession number.

The nucleotide sequences of oprD from the isolates were determined and deposited under GenBank accession no. KM492918.

ACKNOWLEDGMENTS

We thank our coworkers in the Department of Clinical Microbiology and in the EICU, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, who helped us collect, identify, and/or test the samples. We also thank our coworkers in the Department of Pathology, Microbiology, and Immunology at Vanderbilt University School of Medicine for confirming the phenotype of these outbreak strains and for testing imipenem MIC by Etest. We thank Christine Lovly for critically reviewing the manuscript.

Footnotes

Published ahead of print 8 October 2014

REFERENCES

  • 1.Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634–640. 10.1086/338782. [DOI] [PubMed] [Google Scholar]
  • 2.Xiao YH, Wang J, Li Y, MOH National Antimicrobial Resistance Investigation Net. 2008. Bacterial resistance surveillance in China: a report from Mohnarin 2004–2005. Eur. J. Clin. Microbiol. Infect. Dis. 27:697–708. 10.1007/s10096-008-0494-6. [DOI] [PubMed] [Google Scholar]
  • 3.CLSI. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
  • 4.D'Agata EM, Gerrits MM, Tang YW, Samore M, Kusters JG. 2001. Comparison of pulsed-field gel electrophoresis and amplified fragment-length polymorphism for epidemiological investigations of common nosocomial pathogens. Infect. Control Hosp. Epidemiol. 22:550–554. 10.1086/501950. [DOI] [PubMed] [Google Scholar]
  • 5.Pirnay JP, De Vos D, Mossialos D, Vanderkelen A, Cornelis P, Zizi M. 2002. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 4:872–882. 10.1046/j.1462-2920.2002.00281.x. [DOI] [PubMed] [Google Scholar]
  • 6.Kwon DH, Lu CD. 2007. Polyamine effects on antibiotic susceptibility in bacteria. Antimicrob. Agents Chemother. 51:2070–2077. 10.1128/AAC.01472-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chung CT, Niemela SL, Miller RH. 1989. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc. Natl. Acad. Sci. U. S. A. 86:2172–2175. 10.1073/pnas.86.7.2172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Carlone GM, Thomas ML, Rumschlag HS, Sottnek FO. 1986. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. J. Clin. Microbiol. 24:330–332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ohtsubo Y, Sato T, Kishida K, Tabata M, Ogura Y, Hayashi T, Tsuda M, Nagata Y. 2014. Complete genome sequence of Pseudomonas aeruginosa MTB-1, isolated from a microbial community enriched by the technical formulation of hexachlorocyclohexane. Genome Announc. 2(1):e01130-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Livermore DM. 2001. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:247–250. 10.1093/jac/47.3.247. [DOI] [PubMed] [Google Scholar]
  • 11.Yan Y, Mi Z, Liu H, Yang Y, Zhang K, Yang M, Huang W. 2007. Investigation on the antimicrobial resistance characteristics and mechanism of imipenem-resistant Pseudomonas aeruginosa. Chinese J. Nosocomiol. 17:627–630. [Google Scholar]
  • 12.Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582–610. 10.1128/CMR.00040-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, Li LJ. 2010. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int. J. Antimicrob. Agents 35:486–491. 10.1016/j.ijantimicag.2009.12.014. [DOI] [PubMed] [Google Scholar]
  • 14.Diene SM, L'Homme T, Bellulo S, Stremler N, Dubus JC, Mely L, Leroy S, Degand N, Rolain JM. 2013. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France. Int. J. Antimicrob. Agents 42:268–271. 10.1016/j.ijantimicag.2013.06.001. [DOI] [PubMed] [Google Scholar]
  • 15.Huang H, Jeanteur D, Pattus F, Hancock RE. 1995. Membrane topology and site-specific mutagenesis of Pseudomonas aeruginosa porin OprD. Mol. Microbiol. 16:931–941. 10.1111/j.1365-2958.1995.tb02319.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES